[Hyperthyroidism in Graves' disease--antithyroid drug treatment].
PM Schumm-Draeger
Abstract
PM Schumm-Draeger
Abstract
In patients with the first manifestation of hyperthyroidism of Graves' disease, antithyroid drug treatment is the therapy of first choice. Treatment has to be carried out depending on iodine supply of the individual patient with the lowest possible drug dose. Controls of treatment have to be done in short intervals (every 2 weeks) until euthyroidism is reached, afterwards controls of thyroid function have to be done every three months. After euthyroidism is established, the combination of antithyroid drug therapy with thyroid hormones may be useful to avoid hypothyroidism or goiter development during treatment in contrast to a monotherapy with antithyroid drugs. Antithyroid drug treatment has to be carried out for one year. The remission rate of patients is not increased with higher doses of antithyroid drugs or a longer treatment duration. By means of the established methods the determination of TSH receptor antibodies does not help predicting a relapse of hyperthyroidism of Graves' disease in the individual patient at the end of or after treatment. Clinical studies using the human TSH-receptor have to elucidate whether these new methods to measure TSH-receptor-antibodies are of prognostic relevance. Regular follow-up controls after antithyroid drug treatment are necessary to recognize relapse of Graves' disease in time.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In patients with the first manifestation of hyperthyroidism of Graves' disease, antithyroid drug treatment is the therapy of first choice. Treatment has to be carried out depending on iodine supply of the individual patient with the lowest possible drug dose. Controls of treatment have to be done in short intervals (every 2 weeks) until euthyroidism is reached, afterwards controls of thyroid function have to be done every three months. After euthyroidism is established, the combination of antithyroid drug therapy with thyroid hormones may be useful to avoid hypothyroidism or goiter development during treatment in contrast to a monotherapy with antithyroid drugs. Antithyroid drug treatment has to be carried out for one year. The remission rate of patients is not increased with higher doses of antithyroid drugs or a longer treatment duration. By means of the established methods the determination of TSH receptor antibodies does not help predicting a relapse of hyperthyroidism of Graves' disease in the individual patient at the end of or after treatment. Clinical studies using the human TSH-receptor have to elucidate whether these new methods to measure TSH-receptor-antibodies are of prognostic relevance. Regular follow-up controls after antithyroid drug treatment are necessary to recognize relapse of Graves' disease in time.
Key concepts: Medicine, Antithyroid drugs, Graves' disease, Antithyroid agent, Drug, Internal medicine, Goiter, Disease